AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RAPP

Yeleswaram Krishnaswamy sold $20K of RAPP

Yeleswaram Krishnaswamy (Chief Development Officer) sold 404 shares of Rapport Therapeutics, Inc. (RAPP) at $49.90 on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yeleswaram Krishnaswamy
Published Aug 20, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RAPP
Bearish
medium confidence
Mentioned
$RAPP
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RAPPBearishLow
01

Why it matters

Provides fresh, primary‑source data on insider activity for RAPP.

02

Market read

Insider sale of modest size; may cause slight short‑term price pressure.

03

What to watch

Pre‑arranged 10b5‑1 plan may mask timing motives; overall ownership remains substantial.

Relevance 2/10Novelty 4/10Timing: filed post‑market on 2026‑08‑20

Background

SEC Form 4 filing discloses insider transactions required by regulation.

Company-level read

Ticker impact

$RAPPBearishMedium confidence
Context

Chief Development Officer sold 404 shares for $20,159 via a 10b5-1 plan, reducing his stake to 246,022 shares.

Expected impact

Potential modest dip in short-term price as market digests the sell.

Evidence & confidence

Small sale size relative to holdings, but executed under a pre-arranged plan, limits strong inference.

Market effects

Sector

Minimal impact on biotech sector; typical insider sale.

Regional

No broader regional effect.

Global

Limited to investors tracking Rapport Therapeutics.

Counterpoint

What could challenge this read

The sale could be routine liquidity management, not a negative signal.

Key entities

  • person
    Yeleswaram Krishnaswamy

    Chief Development Officer of Rapport Therapeutics, insider seller.

  • company
    Rapport Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker RAPP.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RAPP insider trading history →

Related articles

$RAPPMed

Rapport Therapeutics 3Q 2026: Revenue $0 Net loss $40.2M, EPS $(0.84) — 10-Q Summary

Rapport Therapeutics reported no revenue and a net loss of $40.2M in 3Q 2026, widening from a $26.9M loss in the prior-year quarter. Diluted EPS was $(0.84). The company began Phase 3 trials for RAP-219 in epilepsy and plans further trials in 2027. Collaboration revenue from Tenacia was $20M for the nine months. According to the company, they deferred one program and prioritized another.

tradingview.com
$RAPPHighAI 9/10

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label

SEC EDGAR 8-K
$RAPPMedAI 9/10

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

Rapport Therapeutics (RAPP) closed public offerings of 9.76M shares of common stock at $21.00 per share, $172.5M in convertible notes, and a concurrent private placement of 1.43M shares. Total net proceeds are approximately $410.7M. Proceeds will fund clinical trials, R&D, and general corporate purposes. The notes have a 2.25% interest rate and mature in 2032.

finance.yahoo.com